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Abstract 
 
Hyperglycaemia caused by stress and inflammation is common during critical illness. We 
hypothesised that a latent glucose metabolism disturbance contributes to development of 
hyperglycaemia and that those patients have increased risk for diabetes.  
We included patients with sepsis, acute coronary syndrome and acute heart failure with no 
history of impaired glucose metabolism and divided them in the hyperglycaemia group 
(glucose ≥7.8 mmol/l) and normoglycaemia group. Patients were followed for five years.  
Follow-up was completed for 115 patients in the normoglycaemia group, of which 4 (3.5%) 
developed type 2 diabetes. In the hyperglycaemia group 51 patients finished follow-up and 8 
(15.7%) developed type 2 diabetes. Relative risk in five-year period for patients with 
hyperglycaemia was 4.51 for development of type 2 diabetes.  
Patients with hyperglycaemia during critical illness who are not diagnosed with diabetes 
before or during the hospitalization should be considered a population at increased risk for 
developing diabetes.  
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Introduction 
Hyperglycaemia during critical illness is a common occurrence and has lately been put in 
focus after recent studies had shown that tight glycaemic control can be associated with better 
outcomes in intensive care unit (ICU) patients [1-4]. Hyperglycaemia may occur in patients 
with established diagnosis of diabetes, in patients with previously unrecognised diabetes, but 
in many cases in patients with normal glucose metabolism before and after the acute disease.   
The mechanisms leading to increase in blood glucose during critical illness are complex and 
are a part of stress reaction and inflammatory response. Stress is associated with activation of 
hypothalamic-pituitary-adrenal axis with consequent release of cortisol, but stress response is 
also associated with increase in secretion of other hormones that can induce hyperglycaemia: 
catecholamines, glucagon and growth hormone [5, 6]. Proinflammatory cytokines such as 
interleukin-1 (IL-1) and tumor necrosis factor alpha (TNF-α) cause hyperglycaemia and 
peripheral insulin resistance by promoting the same counter-regulatory hormones, but also by 
altering insulin receptor signalling [7-11]. In muscle and fat cells insulin resistance decreases 
glucose uptake, while in hepatocytes it causes ongoing gluconeogenesis despite 
hyperglycaemia and increased insulin release. Despite hyperglycaemia and peripheral insulin 
resistance insulin concentrations may be normal or even decreased [12-14], due to 
suppression of pancreatic beta-cells caused by proinflammatory cytokines and stimulation of 
alpha receptors by catecholamines [12, 15]. These endocrine and metabolic changes are 
physiologic responses to stress and disease and probably occur in all patients, but evident 
hyperglycaemia is not present in all critically ill patients. It is associated with severity of 
illness, and has been associated with unfavourable outcomes in several acute conditions [1, 2, 
16, 17]. Nevertheless, all patients with severe infections, severe myocardial infarction or other 
critical illnesses do not develop hyperglycaemia and some will have hyperglycaemia even in 
milder disease.  
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Our hypothesis was that hyperglycaemia of critical illness occurs not only as a marker of 
disease severity, but also as a marker of a latent disturbance in glucose metabolism, and that it 
may be associated with increased risk of developing overt disorder of glucose metabolism in 
the period following critical illness. 
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Patients and methods 
This was a single centre study that included patients admitted to the Medical ICU, University 
Hospital Rebro during three years (Jan 2000 – Dec 2002).  
Adult patients who were hospitalised in our ICU with negative history for disorders of 
glucose metabolism [diabetes mellitus (DM), impaired fasting glucose (IFG) or impaired 
glucose tolerance (IGT)] and who were discharged from the hospital alive were considered for 
inclusion. To enable better congruence of groups and comparison of results, we have selected 
only the three most frequent admission diagnoses associated with critical care hyperglycaemia 
in our ICU: sepsis (including severe sepsis and septic shock), acute coronary syndrome (acute 
myocardial infarction and unstable angina) and acute heart failure (without acute ischemia).  
Two groups of patients were formed: hyperglycaemia group and normoglycaemia group. 
Patients were included in the normoglycaemia group if their venous blood glucose (random 
measurements) during the whole ICU stay never exceeded 7.7 mmol/l, while the patients who 
had hyperglycaemia (random venous blood glucose ≥7.8 mmol/l) on at least two occasions 
formed the hyperglycaemia group. Patients with only one hyperglycaemic episode were 
excluded to prevent possible measurement errors. We also excluded patients who were 
receiving corticosteroid treatment during or two months before the ICU admission and those 
with an endocrine disorder that may alter glucose metabolism. Absence of hyperglycaemia 
was confirmed before hospital discharge to rule out patients with previously unrecognised 
diabetes or impaired glucose metabolism, and if the diagnosis of IFG, IGT or DM was 
established, the patient was excluded from the study. Other exclusion criteria were: 
disseminated malignant disease, end-stage chronic disease or any other acute or chronic 
condition that was expected to cause early fatality and hinder follow-up. Patients who were 
unwilling to participate were, also excluded from the study. 
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The follow-up time had to be at least five years, during which, the onset of fasting 
hyperglycaemia, glucose intolerance or diabetes mellitus was noted. We have concluded the 
follow up on April 1
st
 2008.  
 
Definitions 
Impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and diabetes mellitus (DM) 
were defined according to the ADA criteria [18].  
Sepsis, severe sepsis and septic shock were defined according to the usual criteria [19]. 
Acute coronary syndrome, unstable angina and myocardial infarction were defined according 
to the ACC/AHA criteria [20, 21] 
 
Statistical analyses  
MedCalc
TM
 v. 7.2.1.0 statistical software was used for all statistical analyses. Categorical data 
are presented as absolute and relative frequencies, continuous variables as median with inter-
quartile range (IQR). Since the distribution of data of the continuous variables did not always 
follow normal distribution, Wilcoxon’s test was chosen for group comparisons of continuous 
variables. Chi squared test for categorical variables. Statistical significance was set at P<0.05.  
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Results 
During the three inclusion years there were 1154 admissions to our ICU, 685 (59.3 %) with 
the selected diagnoses (sepsis, acute coronary syndrome and acute heart failure), 553 with no 
history of hyperglycaemia or diabetes mellitus prior to the admission. Of those, 511 (92.4 %) 
were discharged from the hospital alive and were considered for inclusion in the study. We 
have excluded 91 patients because of terminal illness (see exclusion criteria), and another 89 
patients who had refused to be included in the study. 
Of the remaining 331 patients, 168 were normoglycaemic during the whole ICU stay and 135 
had two episodes of hyperglycaemia. Only one hyperglycaemic episode was present in 28 
patients who were excluded to rule out errors in measurement.  
We have excluded 26 patients from the hyperglycaemia group, since previously undiagnosed 
diabetes or impaired glucose metabolism (IFG or IGT) was established during the 
hospitalisation. We also excluded 19 patients who had been receiving corticosteroid therapy 
from the hyperglycaemia group.  
Finally, we initiated follow-up for 168 patients in the normoglycaemia group and 90 patients 
in the hyperglycaemia group. The two groups were well matched: there were no significant 
differences between the two groups in age, sex distribution, family history of diabetes, body 
mass index or cholesterol levels (Table 1). Patients in the hyperglycaemia group had higher 
serum triglyceride concentrations than those in normoglycaemia group (median 1.9 vs. 1.4 
respectively; P=0.045).  
During the five years of follow-up, 24 (14.3%) patients in the normoglycaemia group and  
17 (18.8%) patients in the hyperglycaemia group died. There were 29 patients in the 
normoglycaemia group and 22 in the hyperglycaemia group who discontinued their 
assessments and did not enter the final analysis. 
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Of 115 patients in the normoglycaemia group who finished follow-up 16 (13.9%) developed 
fasting hyperglycaemia or impaired glucose tolerance, while 4 (3.5%) were diagnosed as type 
2 diabetes mellitus during the follow-up period. In the hyperglycaemia group 51 patients 
finished follow-up period of which 14 (27.5%) developed IFG or IGT, while 8 (15.7%) 
developed type 2 diabetes (Table 2). Chi-squared test showed this to be a statistically 
significant difference (P=0.001). According to these results, patients with hyperglycaemia 
(defined as glucose ≥7.8 mmol/l) during critical illness had a relative risk for developing IFG 
or IGT of 1.97 (95% CI 1.04-3.73) and for developing type 2 diabetes a relative risk of 4.51 
(95% CI 1.42-14.30). 
When we evaluated the three inclusion diagnoses separately we found that the absolute and 
relative risks for the onset of newly diagnosed impaired glucose metabolism and for type 2 
diabetes were similar among the three subgroups (Table 2). 
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Discussion 
Our results show increased risk for the onset of type 2 diabetes mellitus or impaired glucose 
metabolism (IFG or IGT) in the group of patients who had hyperglycaemia during the ICU 
stay. Patients in the two groups did not differ significantly in the classical risk factors, so the 
higher risk in the hyperglycaemia group could be attributed to the (pre-existent) impairment 
of glucose metabolism, which was latent before the acute illness. During acute illness the 
hyperglycaemic mechanisms in stress and inflammatory response led to revealing of the 
disorder with increased blood glucose concentrations which have returned to normal after the 
insult was weighed down. Nevertheless, the metabolic impairment remained and in some 
patients grew to overt impairment of glucose metabolism: IFG, IGT or even diabetes during 
the years following the acute illness.   
The results are similar among the three diagnoses included in the study: sepsis, acute coronary 
syndrome and acute heart failure. Although the mechanisms leading to hyperglycaemia in 
those three pathophysiologically very different conditions are probably also different, patients 
suffer comparable risks for development of DM, IFG or IGT. This supports the theory that 
hyperglycaemia of acute illness is only triggered by stress and/or inflammation and that there 
is an underlying condition co-responsible for the increase in glucose. Selection of three most 
common diagnoses enabled better comparability of the groups and analysis of the results, but 
limits the ability to draw generalised conclusions, for which we shall need studies on 
unselected ICU populations (surgical and medical). 
There is no universal consensus on the definition of hyperglycaemia during critical illness 
[22]; different studies used different criteria. We have defined hyperglycaemia during critical 
illness as venous blood glucose concentration >7.8 mmol/l, which is a cut-off value in the 
Recommendations of the American Heart Association [23] and a threshold for initiation of 
insulin treatment for ICU patients recommended by the American college of endocrinology 
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[24-26].  We also used personal experience according to which almost all patients have some 
increase in blood glucose during critical illness, so a lower threshold would not be selective 
enough. Higher threshold would probably have hither specificity for patients with an inherent 
glucose metabolism disturbance, but smaller selectivity. The results themselves show that the 
threshold was well chosen. Definitive verdict on the cut-off value for hyperglycaemia in 
critical illness is still to be made, based on past and future studies. 
Despite the three years of inclusion, this was a rather small study in which we were able to 
finalise the follow-up in only 166 patients. Larger, multi-centre studies with longer follow-up 
period will be needed to further substantiate our results. We feel that our results are sufficient 
enough to suggest that the patients with hyperglycaemia during critical illness, who are 
discharged from the hospital with normal glucose control, should be perceived as patients 
with increased risk of developing impaired glucose metabolism or diabetes and should as such 
be regularly monitored and treated appropriately. Change in dietary habits, weight reduction 
and physical activity should be recommended to all. Regular follow-up should also be 
initiated (at least once a year). In addition to fasting plasma glucose measurement and oral 
glucose tolerance test which identify glucose metabolism disturbances, adiponectin could also 
be measured to detect patients with higher risk of insulin intolerance and thus hither risk of 
developing type II diabetes [27].   
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Table 1. Characteristics of patients in normoglycaemia and hyperglycaemia groups. 
Categorical data are presented as absolute and relative frequencies, continuous variables with 
medians with interquartile range. 
 
Characteristic Normoglycaemia group Hyperglycaemia group  
N  168 90  
Age (years) 57 (48-65) 60 (48.5-65) P=0.373 
Sex (F/M) 79 (47.1%) / 89(52.9%) 41 (45.6%) / 49 (54.4) P=0.925 
family history of DM 19 (11.3%) 16 (17.7%) P=0.209 
BMI (kg/m
2
) 28.6 (25.8-35.9) 29.5 (27.1-34.1) P=0.337 
cholesterol (mmol/l) 5.0 (4.3.5.7) 5.6 (4.2-6.8) P=0.339 
triglycerides (mmol/l) 1.4 (1.1-1.9) 1.9 (1.3-2.4) P=0.045 
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Table 2. Incidence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and 
type 2 diabetes mellitus (DM) during the five years follow-up after hospitalisation in the ICU 
for the three most common diagnoses  
 
 
Hyperglycaemia 
group 
Normoglycaemia 
group 
Relative risk 
Finished follow-up 
- sepsis* 
- ACS** 
- heart failure 
all patients 
 
26 
14 
11 
51 
 
66 
29 
20 
115 
 
New IFG or IGT 
- sepsis* 
- ACS** 
- heart failure 
all patients 
 
8 (30.8%) 
4 (21.4%) 
3 (27.2%) 
14 (27.5%) 
 
9 (13.6%) 
4 (13.8%) 
3 (15.0%) 
16 (13.9%) 
 
2.26  (95% CI 0.98-5.21) 
2.07 (95% CI 0.60-7.09) 
1.82 (95% CI 0.44-7.53) 
1.97 (95% CI 1.04-3.73) 
New Type 2 DM 
- sepsis* 
- ACS** 
- heart failure 
all patients 
 
4 (15.4%) 
2 (14.3%) 
2 (18.2%) 
8 (15.7%) 
 
2 (3.0%) 
1 (3.4%) 
1 (5.0%) 
4 (3.5%) 
 
5.07 (95% CI 0.98-26.05) 
4.14 (95% CI 0.40-41.91) 
3.63 (95% CI 0.37-35.72) 
4.51 (95% CI 1.42-14.30) 
Remained 
normoglycaemic 
- sepsis* 
- ACS** 
- heart failure 
all patients 
 
 
14 (53.8%) 
8 (57.8%) 
6 (54.6%) 
29 (56.8%) 
 
 
55 (83.3%) 
24 (82.8%) 
16 (80%) 
95 (82.6%) 
 
* includes severe sepsis and septic shock 
** ACS - acute coronary syndrome (unstable angina and myocardial infarction) 
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We have carefully considered the reviewer's comments and have made changes to the 
manuscript according to them. 
 
Here are the responses to the reviewer's comments point by point 
 
Comment #1: 
The reviewer asks us to specify abbreviations when they are first mentioned in the text, 
anming ''ICU'' as an example.  
 
Response: 
We have added ''intensive care unit'' before the first appearing of ''ICU'' in the text. This 
section of the text (page #3, row#3) now reads:  
 
intensive care unit (ICU)  
 
Comment #2: 
The reviewer askt that the text ''Cushing's syndrome'' and ''of course,'' be deletted from the 
''Materials and methods'' section. 
 
Response: 
The text  ''(e.g. Cushing's syndrome) '' has been deleted from the manuscript (page 5, line 18) 
The text  '' of course,'' has been deleted from the manuscript (page 5, last row) 
 
 
 
Comment #3: 
The reviewer comments the presentation of results in the manuscript, asking that the data are 
presented as median with interquartile range. 
The reviewer also aks that we clarify the reason for using of Wilcoxon's test in the analysis of 
data. 
 
Response: 
In the manuscript, presentation of continuous variables is changed to median with 
interquartile range.  
We have changed the text under ''Statistical analyses section according to both comments and 
it now reads: 
 
MedCalc
TM
 v. 7.2.1.0 statistical software was used for all statistical analyses. 
Categorical data are presented as absolute and relative frequencies, continuous 
variables as median with inter-quartile range (IQR). Since the distribution of data 
of the continuous variables did not always follow the normal distribution, 
Wilcoxon’s test was chosen for group comparisons of continuous variables. Chi 
squared test for categorical variables. Statistical significance was set at P<0.05.  
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Comment #4: 
The reviewer asks us to rewrite the beginning of the Results section to clarify it.  
 
Response:  
The first three paragraphs have been changed to make the beginning of the Results section 
more clear. The term “selected diagnoses” is clarified in the brackets. The three paragraphs 
now read: 
 
During the three inclusion years there were 1154 admissions to our ICU, 685 
(59.3 %) with the selected diagnoses (sepsis, acute coronary syndrome and acute 
heart failure), 553 with no history of hyperglycaemia or diabetes mellitus prior to 
the admission. Of those, 511 (92.4 %) were discharged from the hospital alive and 
were considered for inclusion in the study. We have excluded 91 patients because 
of terminal illness (see exclusion criteria), and another 89 patients who had 
refused to be included in the study. 
Of the remaining 331 patients, 168 were normoglycaemic during the whole ICU 
stay and 135 had two episodes of hyperglycaemia. Only one hyperglycaemic 
episode was present in 28 patients who were excluded to rule out errors in 
measurement.  
We have excluded 26 patients from the hyperglycaemia group, since previously 
undiagnosed diabetes or impaired glucose metabolism (IFG or IGT) was 
established during the hospitalisation. We also excluded 19 patients who had been 
receiving corticosteroid therapy from the hyperglycaemia group.  
 
Comment #4 cont. 
The final comment from the reviewer suggests commenting on alternatives to the use of 
glucose tolerance test    
 
Response: 
We have added a few sentences at the end of the Discussion section in which we comment on 
possible methods during follow-up. Adiponenctin measurement is recommended as a method 
of identifying patients with higher risk for diabetes.  
A reference [27] is added in the last sentence and in the reference list.  
 
The end of the manuscript now reads:  
 
… Change in dietary habits, weight reduction and physical activity should be 
recommended to all. Regular follow-up should also be initiated (at least once a 
year). In addition to fasting plasma glucose measurement and oral glucose 
tolerance test which identify glucose metabolism disturbances, adiponectin could 
also be measured to detect patients with higher risk of insulin intolerance and thus 
hither risk of developing type II diabetes [27].   
 
 
